,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-10-02 02:25:00,The Zacks Research Daily presents the best research output of our analyst team.,0.6325156092643738,0.012341027148067951,0.35514333844184875,positive,0.6201745867729187
1,2017-10-02 02:25:00,"Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), PetroChina (PTR) and Biogen (BIIB).",0.05040673911571503,0.007043007295578718,0.9425503015518188,neutral,0.04336373135447502
2,2017-10-02 02:25:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
3,2017-10-02 02:25:00,"You can see all of today's research reports here >>>

Buy-rated Procter & Gamble 's estimates are trending upward over the last 60 days, hinting analysts' optimism about the company.",0.892289400100708,0.027988867834210396,0.07972174137830734,positive,0.864300549030304
4,2017-10-02 02:25:00,"P&G is known for its strong brand recognition, diversified portfolio, impressive product development capabilities and marketing prowess, as well as strong cash flow productivity.",0.8819406628608704,0.012043415568768978,0.1060158982872963,positive,0.8698972463607788
5,2017-10-02 02:25:00,The company is investing in its brands and products as well as redesigning the supply chain to improve productivity and organic growth.,0.8364386558532715,0.0114588038995862,0.15210258960723877,positive,0.824979841709137
6,2017-10-02 02:25:00,Procter & Gamble is speeding up innovations and investments to counter the softening industry growth.,0.8044552803039551,0.01263556070625782,0.18290908634662628,positive,0.79181969165802
7,2017-10-02 02:25:00,Its productivity improvements and cost-saving efforts are also consistently helping to boost profit level.,0.9573743343353271,0.018996182829141617,0.023629505187273026,positive,0.9383781552314758
8,2017-10-02 02:25:00,"However, major foreign exchange headwind, weak volumes, divestitures and slowing market growth have been hurting sales.",0.021540287882089615,0.9665626883506775,0.011897004209458828,negative,-0.9450224041938782
9,2017-10-02 02:25:00,A soft consumer-spending environment in developed markets and uncertainties in emerging countries also add to the worries.,0.07459784299135208,0.6691628694534302,0.25623923540115356,negative,-0.5945650339126587
10,2017-10-02 02:25:00,Shares of Procter & Gamble have underperformed the Zacks Soap and Cleaning Materials industry so far this year (+8.2% vs. +18.1%).,0.1337699145078659,0.8448710441589355,0.0213590320199728,negative,-0.7111011147499084
11,2017-10-02 02:25:00,(You can read the full research report on Procter & Gamble here >>> ).,0.013788774609565735,0.010992237366735935,0.9752189517021179,neutral,0.0027965372428297997
12,2017-10-02 02:25:00,"ADRs of PetroChina have declined -12.6% over the last six months, underperforming the Zacks International Integrated Energy industry, which has gained +6.2% over the same period.",0.017762795090675354,0.9732865691184998,0.00895057711750269,negative,-0.9555237889289856
13,2017-10-02 02:25:00,"But with higher oil prices helping the state-run giant report a jump in first-half profits, the stock might return to favor.",0.9218412637710571,0.04045798256993294,0.037700772285461426,positive,0.8813832998275757
14,2017-10-02 02:25:00,The energy titan's biggest unit - exploration and production - swung to profitability as oil price soared 50%.,0.9511035680770874,0.022949932143092155,0.02594648487865925,positive,0.9281536340713501
15,2017-10-02 02:25:00,"PTR also experienced strong natural gas demand, while operational optimization helped control costs.",0.9398742318153381,0.01718708500266075,0.04293862730264664,positive,0.9226871728897095
16,2017-10-02 02:25:00,"However, the analyst is concerned over China's decision to cut natural gas prices for industrial users that reduced margins in PTR's gas-wholesale business.",0.021235385909676552,0.9644758701324463,0.014288720674812794,negative,-0.9432404637336731
17,2017-10-02 02:25:00,A limited international operation and an ambitious investment program give investors more reason to be cautious on the stock.,0.669023871421814,0.03608423098921776,0.2948918640613556,positive,0.6329396367073059
18,2017-10-02 02:25:00,"Hence, while being incrementally positive on PTR, the analyst expects the ADRs to remain soft.",0.7549442052841187,0.1201232299208641,0.12493257969617844,positive,0.6348209977149963
19,2017-10-02 02:25:00,(You can read the full research report on PetroChina here >>> ).,0.011692389845848083,0.012626883573830128,0.9756807088851929,neutral,-0.0009344937279820442
20,2017-10-02 02:25:00,Shares of Buy-rated Biogen have outperformed the Zacks Biomedicals/Genetics industry in the last six months (+14.8% vs. +13.3%).,0.6205541491508484,0.35691574215888977,0.022530121728777885,positive,0.2636384069919586
21,2017-10-02 02:25:00,"Biogen has a strong position in the MS market, backed by a wide range of products.",0.6449998617172241,0.009640670381486416,0.3453594744205475,positive,0.6353591680526733
22,2017-10-02 02:25:00,Newly launched Spinraza for spinal muscular atrophy is also off to a promising start.,0.8612034916877747,0.014339210465550423,0.12445732206106186,positive,0.8468642830848694
23,2017-10-02 02:25:00,Spinraza has witnessed faster-than-expected adoption in the U.S. and Biogen is ramping up launch efforts outside the U.S.,0.8792513012886047,0.012840650975704193,0.10790801048278809,positive,0.8664106726646423
24,2017-10-02 02:25:00,The Zacks analyst is also encouraged by Biogen's efforts to diversify beyond MS to other areas like Alzheimer's.,0.9134093523025513,0.012965856119990349,0.07362479716539383,positive,0.9004434943199158
25,2017-10-02 02:25:00,"The company also spun off its hemophilia business in Feb 2017, which allows it to focus on neurology, its key area of expertise.",0.095277801156044,0.07772102952003479,0.8270012140274048,neutral,0.017556771636009216
26,2017-10-02 02:25:00,Estimates have moved up ahead of the Q3 earnings results.,0.6949015259742737,0.04632274806499481,0.2587757706642151,positive,0.6485787630081177
27,2017-10-02 02:25:00,The company has a positive record of earnings surprises in recent quarters.,0.9442597031593323,0.02228577248752117,0.03345456346869469,positive,0.9219739437103271
28,2017-10-02 02:25:00,"However, Biogen has its own set of challenges.",0.01796545274555683,0.01838168501853943,0.9636529088020325,neutral,-0.00041623227298259735
29,2017-10-02 02:25:00,"Despite its position in the MS market, the emergence of new PML cases for Tecfidera are likely to weigh heavily on the stock along with pipeline setbacks.",0.0884091705083847,0.8572754859924316,0.05431527644395828,negative,-0.7688663005828857
30,2017-10-02 02:25:00,"Meanwhile, the recent Ocrevus launch by Roche may create pressure on Tysabri's sales.",0.02309536561369896,0.9486743211746216,0.028230266645550728,negative,-0.9255789518356323
31,2017-10-02 02:25:00,(You can read the full research report on Biogen here >>> ).,0.013879170641303062,0.012286399491131306,0.9738344550132751,neutral,0.0015927711501717567
32,2017-10-02 02:25:00,"Other noteworthy reports we are featuring today include Accenture (ACN), Halliburton (HAL) and Norfolk Southern (NSC).",0.035140737891197205,0.0053764088079333305,0.9594828486442566,neutral,0.0297643281519413
33,2017-10-02 02:25:00,"It's hard to believe, even for us at Zacks.",0.08736173063516617,0.254048228263855,0.6585900187492371,neutral,-0.1666865050792694
34,2017-10-02 02:25:00,"But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.",0.8417097330093384,0.03877422213554382,0.11951606720685959,positive,0.8029354810714722
35,2017-10-02 02:25:00,And this outperformance has not just been a recent phenomenon.,0.07535909861326218,0.015217346139252186,0.9094235301017761,neutral,0.060141753405332565
36,2017-10-02 02:25:00,Over the years it has been remarkably consistent.,0.6927107572555542,0.013971779495477676,0.29331743717193604,positive,0.6787389516830444
37,2017-10-02 02:25:00,"From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over.",0.754240095615387,0.14411918818950653,0.10164069384336472,positive,0.6101208925247192
38,2017-10-02 02:25:00,Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.,0.5744941830635071,0.01052891369909048,0.41497692465782166,positive,0.5639652609825134
39,2017-10-02 02:25:00,Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings.,0.1108352467417717,0.007436841260641813,0.881727933883667,neutral,0.1033984050154686
40,2017-10-02 02:25:00,He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Preview reports.,0.025165576487779617,0.008906112052500248,0.9659282565116882,neutral,0.016259465366601944
41,2017-10-02 02:25:00,"If you want an email notification each time Sheraz publishes a new article, please click here>>>

Want the latest recommendations from Zacks Investment Research?",0.024681570008397102,0.01500809658318758,0.9603102803230286,neutral,0.009673473425209522
42,2017-10-02 02:25:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
43,2017-10-02 02:25:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
44,2017-10-02 02:25:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
